Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study
Table 3
Summary of the meta-analysis results.
Categories
Trials
HR (95% CI)
(%)
Pretreatment
11 (7398)
2.56 (1.78-3.68)
71.5
<0.001
5.06
<0.001
Study region
0.245
Taiwan
3 (2256)
2.71 (1.78-4.12)
10.4
0.327
4.67
<0.001
Korea
5 (4084)
2.80 (1.44-5.46)
86.4
<0.001
3.03
0.002
Others
3 (1058)
1.90 (1.23-2.93)
0.0
0.657
2.91
0.004
Hepatitis type
0.542
CHB
5 (3586)
3.16 (1.77-5.63)
67.1
0.016
3.89
<0.001
CHC
5 (2888)
2.17 (1.42-3.32)
57.9
0.050
3.56
<0.001
ALC
1 (924)
1.46 (0.73-2.94)
NA
NA
1.06
0.287
Cut-off value
0.600
≥1.0
5 (2461)
1.62 (1.35-1.95)
36.8
0.176
5.15
<0.001
<1.0
5 (4251)
3.79 (2.15-6.67)
55.7
0.060
4.61
<0.001
NR
1 (686)
2.04 (1.10-3.79)
NA
NA
2.26
0.024
Sample size
0.643
≥800
5 (5095)
2.79 (1.76-4.42)
52.2
0.079
4.35
<0.001
<800
6 (2303)
2.37 (1.36-4.13)
77.2
0.001
3.03
0.002
Analysis method
0.373
Multivariate
7 (4873)
2.37 (1.82-3.09)
41.2
0.116
6.36
<0.001
Univariate
4 (2525)
2.90 (1.30-6.46)
86.3
<0.001
2.60
0.009
Posttreatment
5 (2884)
3.69 (2.52-5.42)
7.8
0.362
6.68
<0.001
CHB: chronic hepatitis B; CHC: chronic hepatitis C; ALC: alcoholic liver cirrhosis; NR: none reported; : value for heterogeneity based on the test; : value for statistical significance based on the test; : value for statistical outcome based on multivariate metaregression analysis; : random-effect model.
